GHK-Cu

Typical use cases

Dosing guidelines

Titration

Community protocols typically describe beginning at the lower end (~1 mg/day) and adjusting within the reported range, frequently using on/off cycling rather than open-ended daily use; framed here neutrally as reported practice, not a recommendation.

Reconstitution

For injectable lyophilized powder: commonly reconstituted with bacteriostatic water, often at ~1 mg per 1 mL (or 2 mg/mL for a more concentrated solution). Add diluent slowly down the vial wall and swirl gently; do not shake. (Topical/cosmetic formulations are pre-formulated — N/A for reconstitution.)

Injection sites

Subcutaneous injection into fatty tissue (abdomen, flank/love handles, or thigh) for injectable use; topically the complex is applied directly to the skin as a serum or cream.

Storage & handling

Lyophilized powder: store cold and protected from light (refrigerated, or frozen for long-term). After reconstitution, refrigerate (2-8°C); reconstituted solution is commonly used within about 21-28 days due to copper oxidation. The complex is most stable around pH 6.5-7.5. Topical products: store per label, away from heat and light.

Side effects

• Injection-site reaction (redness, swelling, bruising) Mild · Common
• Mild nausea or lightheadedness (often only after first doses) Mild · Uncommon
• Fatigue or transient flu-like feeling Mild · Uncommon
• Headache or dizziness Mild · Uncommon
• Skin irritation or contact sensitivity (topical use) Mild · Uncommon
• Theoretical copper accumulation/overload with chronic high systemic dosing Moderate · Rare

Research summary

GHK-Cu was isolated from human plasma by Loren Pickart in 1973, and the active tripeptide was identified as glycyl-L-histidyl-L-lysine in 1977; plasma levels fall from roughly 200 ng/mL at age 20 to about 80 ng/mL by age 60, which underlies its framing as an age-declining repair signal. The evidence base is strongest in preclinical work and in topical/cosmetic human studies: animal models show accelerated healing of diabetic, ischemic, and surgical wounds with reduced TNF-alpha and modulation of matrix metalloproteinases, while cell studies show stimulation of collagen, elastin, and glycosaminoglycan synthesis and suppression of pro-inflammatory IL-6. Gene-expression analyses (Pickart et al.) report that GHK can up- or down-regulate on the order of 4,000+ human genes, including DNA-repair and antioxidant pathways, which the authors propose explains its diverse regenerative and protective actions. Controlled cosmetic studies of GHK-Cu serums (typically 1-3 ppm topical) report increased dermal collagen and visible skin improvements, in some comparisons exceeding vitamin C or comparable to retinoic acid. Limitations are significant: most human data concern topical application and small cosmetic studies, robust large-scale randomized human trials of injectable GHK-Cu are lacking, and systemic injectable use is essentially off-label/research-grade with no established human efficacy or long-term safety dataset. Plasma half-life is very short (degraded rapidly by peptidases; commonly cited as minutes), and the copper component raises a theoretical concern about cumulative copper load with chronic high-dose systemic use. Overall, GHK-Cu is well characterized mechanistically and has solid topical/preclinical support, but injectable systemic protocols remain extrapolated from cosmetic and animal data rather than confirmed by human clinical trials.

Key references

• https://en.wikipedia.org/wiki/Copper_peptide_GHK-Cu
• https://pmc.ncbi.nlm.nih.gov/articles/PMC4508379/
• https://pubmed.ncbi.nlm.nih.gov/29986520/
• https://www.mdpi.com/2079-9284/5/2/29
• https://clinicaltrials.gov/study/NCT07437586

Related compounds